ArticleAntimicrobial agents and chemotherapy2015
Candida parapsilosis Resistance to Fluconazole: Molecular Mechanisms and In Vivo Impact in Infected Galleria mellonella Larvae.
Article in Antimicrobial agents and chemotherapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 78 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
78 citing papers in PubMed, 122 citations in OpenAlex.
- First Report of Fluconazole-Resistant Candida parapsilosis Harbouring the G458S ERG11p Substitution in a Brazilian Hospital.Mycoses · 2026Article
- In vitro activity of eight antifungal drugs against clinical and hospital isolates of Candida parapsilosis complex; a multicenter study, 2023-2024.BMC infectious diseases · 2026Article
- Persistence and spread of fluconazole-resistantMicrobial genomics · 2026Article
- Identification ofMicrobiology spectrum · 2026Article
- Emerging antifungal resistance in Candida parapsilosis: the end of the innocence.npj antimicrobials and resistance · 2025Review
- Clinical impact of fluconazole-resistantFuture microbiology · 2025Review
- Vaginal mycobiome characteristics and therapeutic strategies in vulvovaginal candidiasis (VVC): differentiating pathogenic species and microecological features for stratified treatment.Clinical microbiology reviews · 2025Review
- Resistance to Azoles inJournal of fungi (Basel, Switzerland) · 2025Article
- Review
- Threats from theMicrobiology and molecular biology reviews : MMBR · 2024Review
- Clinical Characteristics of Candidemia Due toJournal of fungi (Basel, Switzerland) · 2024Article
- Analysis of clinicalAntimicrobial agents and chemotherapy · 2024Article
- Hybrid Materials Obtained by Immobilization of Biosynthesized Ag Nanoparticles with Antioxidant and Antimicrobial Activity.International journal of molecular sciences · 2024Article
- Standardization of polymerase chain reaction for detection of fluconazole resistance targeting Y132F mutation inCurrent medical mycology · 2024Article
- Antifungal Resistance and Genotyping of ClinicalJournal of fungi (Basel, Switzerland) · 2023Article
- Analysis of clinicalbioRxiv : the preprint server for biology · 2023Article
- A 14-Year Cohort of Candidemia in the Pediatric Population in a Tertiary Center in Jerusalem: Clinical Characteristics, Antifungal Susceptibility, and Risk Factors for Mortality.Journal of fungi (Basel, Switzerland) · 2023Article
- Review
- Application of Novel Short Tandem Repeat Typing forMicroorganisms · 2023Article
- Worldwide emergence of fluconazole-resistant Candida parapsilosis: current framework and future research roadmap.The Lancet. Microbe · 2023Review
18 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Candida parapsilosis is the main non-albicans Candida species isolated from patients in Latin America. Mutations in the ERG11 gene and overexpression of membrane transporter proteins have been linked to fluconazole resistance. The aim of this study was to evaluate the molecular mechanisms in fluconazole-resistant strains of C. parapsilosis isolated from critically ill patients. The identities of the nine collected C. parapsilosis isolates at the species level were confirmed through molecular identification with a TaqMan qPCR assay. The clonal origin of the strains was checked by microsatellite typing. The Galleria mellonella infection model was used to confirm in vitro resistance. We assessed the presence of ERG11 mutations, as well as the expression of ERG11 and two additional genes that contribute to antifungal resistance (CDR1 and MDR1), by using real-time quantitative PCR. All of the C. parapsilosis (sensu stricto) isolates tested exhibited fluconazole MICs between 8 and 16 μg/ml. The in vitro data were confirmed by the failure of fluconazole in the treatment of G. mellonella infected with fluconazole-resistant strains of C. parapsilosis. Sequencing of the ERG11 gene revealed a common mutation leading to a Y132F amino acid substitution in all of the isolates, a finding consistent with their clonal origin. After fluconazole exposure, overexpression was noted for ERG11, CDR1, and MDR1 in 9/9, 9/9, and 2/9 strains, respectively. We demonstrated that a combination of molecular mechanisms, including the presence of point mutations in the ERG11 gene, overexpression of ERG11, and genes encoding efflux pumps, are involved in fluconazole resistance in C. parapsilosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.